The increasing prevalence of NTHi [76, 77], alongside the changing landscape of CF lung infection with the availability of CFTR modulators, may place greater importance on handling and treating NTHi infections in people with CF [8, 11,78]. This evidence concerns the gene CFTR and cystic fibrosis.